Cord blood transplantation (CBT), an important modality within hematopoietic stem cell transplantation, has faced increasing competition in recent years from alternative donor strategies such as haploidentical transplantation. As a result, the field is undergoing a period of reassessment and transformation. Nevertheless, CBT retains irreplaceable value in selected patient populations, while its potential applications in cell and gene therapy as well as regenerative medicine continue to expand.

As a bellwether for innovation in oncology drug therapy, the evolution of lymphoma treatment reflects the broader trajectory of modernization in Chinese oncology. From the introduction of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in 1992—laying the foundation for chemotherapy—to successive breakthroughs in targeted therapy, immunotherapy, and cellular therapy, China’s lymphoma care has undergone 35 years of transformation, progressing from “following” to “running alongside,” and now to “leading.”

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Symposium, was held in Changsha. During the meeting, Professor Yajing Xu, Executive Chair and Director of Hematology at Xiangya Hospital, Central South University, was invited by Hematology Frontier to share her insights on the clinical challenges of long-term follow-up after hematopoietic stem cell transplantation (HSCT), standardized management models, and pathways for primary care collaboration. Her discussion aimed to promote the standardization of follow-up systems and improve long-term survival and quality of life for patients.